阿托伐他汀联合低分子肝素治疗肾病综合征的疗效观察  

Atorvastatin combined with low molecular weight heparin in treatment of nephrotic syndrome

作　　者：张连云[1] 王树龙[1] 郭明好[2] 

机构地区：[1]新乡医学院第一附属医院肾病风湿免疫科,卫辉453100 [2]新乡医学院第三附属医院肾病科,453000

出　　处：《国际医药卫生导报》2017年第11期1760-1763,共4页International Medicine and Health Guidance News

摘　　要：目的探讨阿托伐他汀联合低分子肝素治疗肾病综合征的疗效。方法选择本院2014年1月至2015年12月收治的200例肾病综合征患者，按照治疗方法的不同分为观察组和对照组，各100例。对照组在常规治疗基础上给予低分子肝素，观察组在对照组治疗基础上给予阿托伐他汀，观察两组治疗效果及患者血脂、肾功能各指标的改善情况。结果两组血清白蛋白（Alb）、24h尿蛋白定量（Pr）、血尿素氮（BUN）指标均明显改善，与治疗前比较，均P〈0．05；治疗后，观察组Alb、Pr、BUN指标分别为（26．97±3．65）g，L、（1．97±0．81）mmol／L、（6．41±2．29）mmol/L，与对照组的（23．76±3．31）g/L、（2．72±1．92）mmol／L、（7．17±2．88）mmol/L比较更趋于正常，效果优于对照组，均P〈0．05；两组血清总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL—C）和低密度脂蛋白胆固醇（LDL—C）均明显改善，与治疗前比较，均尸〈0．05，治疗后，观察组TC、TG、HDL-C、LDL—C指标分别为（3．67±0．99）mmol/L、（1．25±0．77）mmol／L、（3．96±1．33）mmol/L、（3．15±1．36）mmol／L，对照组分别为（6．12±1．25）mmol/L、（2．17±1．67）mmol/L、（3．31±1．25）mmol／L、（5．33±2．91）mmol／L，观察组更趋于正常，效果优于对照组，均P〈0．05；观察组和对照组的总有效率分别为87．0％和68．0％，组间比较，P〈0．05。两组均未见明显不良反应。结论阿托伐他汀联合低分子肝素治疗肾病综合征能有效改善患者血脂、肾功能指标，疗效确切。Objective To investigate the efficacy of atorvastatin combined with low molecular weight heparin in the treatment ofnephrotic syndrome. Methods 200 cases ofnephrotic syndrome treated at our hospital from January, 2014 to December, 2015 were divided into an observation group and a control group according to different treatment methods, 100 cases for each group. In the addition of routine treatment, the control group was treated with low molecular weight heparin and the observation group with atorvastatin and low molecular weight heparin. The therapeutic effects of the two groups and the improvement of the blood lipid and renal function of thepatients were observed. Results The serum albumin two group （ Alb ） , 24 h urinary protein （ Pr ） , and blood urea nitrogen （ BUN ） were significantly improved in both group after treatment,. P 〈 0.05 After treatment, Alb, Pr, and BUN were （ 26.97±3.65 ） g/L, （ 1.97±0.81 ） mmol/L, and （ 6.41±2.29 ） mmol/L in the observation group and were （ 23.76±3.31 ） g/L, （ 2.72±1.92 ） mmol/L, and （ 7.17±2.88 ） mmol/L in the control group, all P 〈 0.05. The serum levels of total cholesterol （ TC ） , three glycerol （ TG ） , high density lipoprotein cholesterol （ HDL-C ） , and low density lipoprotein cholesterol （ LDL-C ） were significantly improved in both groups after treatment, P 〈 0.05. After treatment, the levels ofTC, TG, HDL-C, and LDL-C were （ 3.67±0.99 ） mmol/L, （ 1.25±0.77 ） mmol/L, （ 3.96±1.33 ） mmol/L, and （ 3.15±1.36 ） mmol/L in the observation group and were （6.12±1.25） mmol/L, （2.17±1.67） mmol/L, （3.31±1.25） mmol/L, and （5.33±2.91） mmol/L in the control group, all P〈0.05. The total efficacy was 87.0% in the observation group and 68.0% in the control group, P 〈 0.05. No obvious adverse reactions occurred in both groups. Conclusions Atorvastatin combined with low molecular weight hepadn in the treatment of nephrotic syndrome can effectively improve the blood lipid and renal

关 键 词：阿托伐他汀 低分子肝素 肾病综合征 血脂 肾功能 

分 类 号：R692[医药卫生—泌尿科学]